Netarsudil Mesylate
Brand name: Rhopressa
Rank #212 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$65.6M
Total Cost
129,116
Total Claims
$65.6M
Total Cost
2,725
Prescribers
$508
Cost per Claim
28,274
Beneficiaries
201,021
30-Day Fills
$24K
Avg Cost/Provider
47
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$65.6M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $65.6M total
Top Prescribers of Netarsudil Mesylate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Analisa Arosemena | Ophthalmology | Miami Beach, FL | 1,675 | $616K |
| 2 | Azizur Rahman | Ophthalmology | Rockford, IL | 613 | $403K |
| 3 | Scott Schecter | Optometry | Fort Lauderdale, FL | 917 | $373K |
| 4 | David Sola-Del Valle | Ophthalmology | Danville, IL | 485 | $363K |
| 5 | Howard Kushnick | Ophthalmology | Allentown, PA | 582 | $352K |
| 6 | Jeffrey Rabowsky | Ophthalmology | Sacramento, CA | 389 | $318K |
| 7 | Omar Mobin-Uddin | Ophthalmology | New Brunswick, NJ | 435 | $294K |
| 8 | Sarah Anis | Ophthalmology | Providence, RI | 571 | $294K |
| 9 | Omar Shoukfeh | Ophthalmology | Lubbock, TX | 569 | $276K |
| 10 | Kundandeep Nagi | Ophthalmology | San Antonio, TX | 490 | $275K |
| 11 | Amber Dobler-Dixon | Ophthalmology | Amarillo, TX | 548 | $258K |
| 12 | Jacqueline Gabay | Ophthalmology | Elmwood Park, NJ | 422 | $246K |
| 13 | Richard Quinones | Ophthalmology | Homewood, IL | 433 | $241K |
| 14 | Fiaz Zaman | Ophthalmology | Houston, TX | 382 | $234K |
| 15 | Reza Razeghinejad | Ophthalmology | Philadelphia, PA | 427 | $226K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 209 | Treprostinil Diolamine (Orenitram Er) | $68.2M | 5,964 |
| 210 | Esomeprazole Magnesium (Esomeprazole Magnesium) | $66.3M | 964,193 |
| 211 | Dabigatran Etexilate Mesylate (Dabigatran Etexilate) | $66.0M | 220,652 |
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology